EGFR and cancer: Gefitinib is an inhibitor of the EGFR tyrosine kinase domain and effectively suppresses cancer cell proliferation by downregulating EGFR signaling, particularly within TNBC (Herbst et al., 2004; Bernsdorf et al., 2011).